# Submitting an Abstract for STATGEN2024


> Presentation title:

Assessing the Evidence for a Causal Effect of Fibromuscular Dysplasia on
Chronic Kidney and Biomarkers of Kidney Function: A Mendelian
Randomization Study

> Abstract (max 1200 characters):

Fibromuscular dysplasia (FMD) is a noninflammatory and
nonatherosclerotic disease of artery walls that often affects
medium-sized artery beds, including those of the renal
arteries<sup>1–3</sup>. Multiple studies implicated renal artery FMD in
impaired kidney function<sup>4–7</sup>. We sought to quantify causal
effects of FMD on chronic kidney disease (CKD) in a two-sample Mendelian
randomization study with GWAS summary statistics. We used genetic
instruments for FMD from a meta-analysis of six genome-wide association
studies of multifocal FMD<sup>8</sup>. For each putative outcome
variable, we performed a two-sample Mendelian randomization analysis
with inverse-variance weighted, weighted median, MR-Egger, weighted
mode, and simple mode methods. We obtained association effect estimates
for putative outcomes from publicly available summary statistics from UK
Biobank GWAS<sup>9</sup>. We considered three different p-value
thresholds when choosing relevant SNP instruments for MR analyses. All
five methods showed no evidence of a causal effect of FMD on CKD. To
further evaluate our findings, we performed sensitivity analyses to
assess evidence of horizontal pleiotropy and other sources of
confounding<sup>10,11</sup>.

## References

<div id="refs" class="references csl-bib-body" entry-spacing="0"
line-spacing="2">

<div id="ref-olin2011diagnosis" class="csl-entry">

<span class="csl-left-margin">1.
</span><span class="csl-right-inline">Olin, J. W. & Sealove, B. A.
Diagnosis, management, and future developments of fibromuscular
dysplasia. *Journal of vascular surgery* **53**, 826–836 (2011).</span>

</div>

<div id="ref-mousa2013renal" class="csl-entry">

<span class="csl-left-margin">2.
</span><span class="csl-right-inline">Mousa, A. Y. & Gill, G. Renal
fibromuscular dysplasia. in *Seminars in vascular surgery* vol. 26
213–218 (Elsevier, 2013).</span>

</div>

<div id="ref-sang1989etiologic" class="csl-entry">

<span class="csl-left-margin">3.
</span><span class="csl-right-inline">Sang, C. N. *et al.* Etiologic
factors in renovascular fibromuscular dysplasia. A case-control study.
*Hypertension* **14**, 472–479 (1989).</span>

</div>

<div id="ref-hunt1965hypertension" class="csl-entry">

<span class="csl-left-margin">4.
</span><span class="csl-right-inline">Hunt, J. C. *et al.* Hypertension
caused by fibromuscular dysplasia of the renal arteries. *Postgraduate
Medicine* **38**, 53–63 (1965).</span>

</div>

<div id="ref-oliva2018kidneys" class="csl-entry">

<span class="csl-left-margin">5.
</span><span class="csl-right-inline">Oliva-Damaso, N. *et al.* Kidneys
are key in secondary hypertension: A case of fibromuscular dysplasia.
*The Lancet* **392**, 2298 (2018).</span>

</div>

<div id="ref-mounier2002parenchymal" class="csl-entry">

<span class="csl-left-margin">6.
</span><span class="csl-right-inline">Mounier-Vehier, C. *et al.*
Parenchymal consequences of fibromuscular dysplasia renal artery
stenosis. *American journal of kidney diseases* **40**, 1138–1145
(2002).</span>

</div>

<div id="ref-van2018renal" class="csl-entry">

<span class="csl-left-margin">7.
</span><span class="csl-right-inline">Twist, D. J. van, Leeuw, P. W. de
& Kroon, A. A. Renal artery fibromuscular dysplasia and its effect on
the kidney. *Hypertension Research* **41**, 639–648 (2018).</span>

</div>

<div id="ref-georges2021genetic" class="csl-entry">

<span class="csl-left-margin">8.
</span><span class="csl-right-inline">Georges, A. *et al.* Genetic
investigation of fibromuscular dysplasia identifies risk loci and shared
genetics with common cardiovascular diseases. *Nature communications*
**12**, 6031 (2021).</span>

</div>

<div id="ref-neale_lab_gwas" class="csl-entry">

<span class="csl-left-margin">9.
</span><span class="csl-right-inline">UK biobank GWAS. (2018).</span>

</div>

<div id="ref-skrivankova2021strengthening" class="csl-entry">

<span class="csl-left-margin">10.
</span><span class="csl-right-inline">Skrivankova, V. W. *et al.*
Strengthening the reporting of observational studies in epidemiology
using mendelian randomization: The STROBE-MR statement. *Jama* **326**,
1614–1621 (2021).</span>

</div>

<div id="ref-burgess2017sensitivity" class="csl-entry">

<span class="csl-left-margin">11.
</span><span class="csl-right-inline">Burgess, S., Bowden, J., Fall, T.,
Ingelsson, E. & Thompson, S. G. Sensitivity analyses for robust causal
inference from mendelian randomization analyses with multiple genetic
variants. *Epidemiology* **28**, 30–42 (2017).</span>

</div>

</div>
